Dr. Andrew Goodwin is a pulmonary intensivist committed to improving the health and well-being of critically ill patients through patient-centered care and clinical and translational research. His clinical interests include the hemodynamic management of septic shock and ventilation strategies for ARDS as well as strategies to mitigate ICU delirium. He also performs translational research focused on the potential role that micro RNA play in the endothelial dysfunction of sepsis and ARDS. In particular, he and his collaborators are focused on identifying the role that circulating miRNA have on endothelial cell gene expression and function and their potential use as a therapeutic in these syndromes. Additionally, he investigates the impact of patient factors such as race and comorbidities as well as hospital factors such as location and size on the outcomes of critical illness. His long-range goal is to improve the outcomes of critically ill patients through new therapeutics and optimal bedside care.